News

Kenvue offers both a great short-term and long-term payoff to investors.

Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.

The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.

Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.

Investing.com -- Johnson & Johnson will not enter the obesity drug market, Chief Executive Officer Joaquin Duato said Tuesday. The company plans to concentrate on cancer and neuroscience instead.

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The average retired worker receives roughly $2,000 a month from Social Security. For many retirees, that covers only part of the budget. Building a second Social Security-sized check from dividends can help cover housing, healthcare, travel, family support, or simply provide a larger margin of safety in retirement. The challenge is not finding the right stock. ... How to Build $3,000 a Month in Dividend Income to Cover the Average Social Security Check

Johnson & Johnson (JNJ) spent 2025 proving it could lose a multibillion-dollar drug and still grow. Now it wants to show it can keep doing that for years. On June 13, the company reported results from a late-stage trial of its blood-cancer drug TALVEY, and the data landed at one of the year's ...

Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HCM, expanding the drug's market reach.

The scenario looks like this: a 63-year-old has built up $850,000 over a working lifetime, watched 2022 and a few scary headlines since, and parked almost all of it in CDs, money market funds, and short Treasuries paying roughly 4%. That throws off about $34,000 a year in interest. It feels prudent. It is also ... Playing It Safe at 63 With $850,000 in Cash and Bonds Is Quietly Costing This Retiree About $34,000 a Year

Joaquin Duato made the comments at a CEO summit in London, where he also said AI is already helping J&J develop medicines faster

Monika Saxena joins the casual-dining chain after eight years as EVP of brand marketing at LongHorn Steakhouse.

AZN shares fell after a camizestrant setback, but blockbuster drugs, oncology growth and a deep pipeline support long-term targets.

Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.

The investment will add J&J’s manufacturing, packaging and distribution capabilities to meet growing demand for its contact lenses.

Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.

Wondering if Johnson & Johnson at around US$235.66 is still a solid deal or starting to look fully priced? This article walks through the numbers so you can judge the stock's value with more confidence. The stock closed at US$235.66 and has returns of 1.5% over 7 days, 3.9% over 30 days, 13.7% year to date, 55.6% over 1 year, 56.6% over 3 years, and 65.6% over 5 years. This gives useful context before looking at valuation. Recent headlines around Johnson & Johnson have focused on its...

Two retirees walk into retirement with the same amount of money. One builds a portfolio that pays $120,000 a year but barely grows. The other settles for $65,000 a year and focuses on dividend growth. At first glance, the first retiree appears to have won. Twenty-five years later, the second retiree may have collected more ... The Retiree Who Chose $65,000 Instead of $120,000 and Ended Up Richer

The iShares Core Dividend Growth ETF (NYSEARCA:DGRO) was built for investors who want a paycheck that gets bigger every year, not a yield chase. DGRO tracks the Morningstar US Dividend Growth Index, screening for companies with at least five consecutive years of dividend growth and payout ratios under 75%. The fund pays a roughly 2.2% ... 64 Years of Raises: How DGRO Finds Companies That Never Cut Dividends

The investment is anticipated to enhance J&J’s supply chain resilience regarding production of its ACUVUE contact lenses.

A rank-and-file member of Congress earns $174,000 per year. A dividend portfolio can generate the same level of income without a campaign, constituents, or a weekly commute to Washington. Unlike a salary, however, this income is tied to capital, which means the size of the portfolio matters far more than the title attached to the ... This $1.7 Million Portfolio Pays More Than a Member of Congress

PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.

AZN wins FDA approval to expand Truqap's use in PTEN-deficient prostate cancer, backed by phase III data showing improved outcomes and broader use.

Although Wall Street has spent the better part of two years cheering an artificial intelligence buildout that has dragged the Nasdaq 100 up roughly 30% over the past year, the technology-packed Nasdaq Composite is starting to wobble at the worst possible moment. The benchmark S&P 500 has slipped, with SPY off about 4% in the ... Today’s AI market hits all 5 warning signs that preceded 2000 Nasdaq crash.

The latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.

Johnson & Johnson (NYSE:JNJ) reported breakthrough Phase 2/3 ENERGY trial results for IMAAVY (nipocalimab) in warm autoimmune hemolytic anemia, a rare anemia with no current FDA approved therapies. The drug significantly improved hemoglobin levels and fatigue in trial patients, with a safety profile consistent with prior use. These data supported a supplemental Biologics License Application, which has received U.S. FDA Priority Review. IMAAVY is also being studied across multiple autoimmune...

We recently published Jim Cramer Didn’t Hold Back On SpaceX’s IPO & Discussed These 12 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer. Johnson & Johnson (NYSE:JNJ)’s shares are up by 53% over the past year and by 15% year-to-date. Leerink Partners discussed the firm on May 13th as […]

Building $3,000 a month in dividend income before age 50 can transform the way you think about work. While it may not fully replace a salary, it can cover a mortgage payment, health insurance, or a large share of household expenses, creating the freedom to reduce hours, change careers, take a sabbatical, or pursue work ... How to Build $3,000 a Month in Dividend Income Before You Turn 50

A $2 million dividend portfolio for retirement sounds like you’ve arrived. For a retired couple living in New York, however, the headline portfolio value tells only part of the story. What ultimately matters is not the income shown on a brokerage statement, but the amount that remains available to spend after taxes and other income-related ... What a $2 Million Dividend Portfolio Actually Pays a New York Retiree After Taxes

The average retired worker receives roughly $23,700 per year from Social Security. A $750,000 portfolio dedicated to income generation can surpass that figure at virtually any reasonable yield level. The question is not whether the portfolio can outproduce the average Social Security benefit. The question is how much risk must be taken to achieve that ... A $750,000 Portfolio That Quietly Pays You More Than the Average Social Security Check